Ten drugs in pre-registration phase have potential to reach blockbuster status by 2025: GlobalData
Amgen and Allergan’s biosimilar candidate to Roche’s Rituxan (rituximab) shows the greatest potential of these drugs
Out of all…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Amgen
Healthcare industry sets 52 deals worth US$9.5 bn in Oct’19
The industry also reported 85 venture capital (VC) deals worth US$1.7 billion in October 2019, compared to the last 12-month…
37 M&A deals worth $18.9 bn in Aug 2019: GlobalData Report
Amgen’s proposed acquisition of Otezla from Celgene for $13.4 billion provides 71 per cent to deal value
Dr Mahesh Bhalgat appointed as Chief Operating Officer at Syngene International
Dr Bhalgat is recognised for his contribution to the commercialization of diagnostic kits, biopharmaceuticals and WHO…
Valeant picks up AstraZeneca psoriasis drug after Amgen exit
Valeant said that it would make an upfront payment of $100 million to AstraZeneca
Canada's Valeant Pharmaceuticals International…
Novartis in global partnership with Amgen
To develop and commercialise pioneering neuroscience treatments
Novartis has entered into a global collaboration with Amgen to…
DRL in collaboration with Amgen in India
DRL to market and distribute Amgen’s Repatha, Kyprolis and BLINCYTO in India upon approval
Dr Reddy’s Laboratories (DRL) has…
Fortune announces list of 2015 ‘World’s Most Admired Companies’
Fortune magazine has announced its list of 2015 'World’s Most Admired Companies.' The companies on the world’s most admired list…